CD39 Identifies Tumor-Reactive CD8 T cells in Patients With Lung Cancer
ABSTRACT The repertoire of tumor-infiltrating lymphocytes (TILs) can be vast, and many of these TILs are not endowed with tumor reactivity. While a number of reports have shown that tumor-reactive TILs express CD39, few reports have demonstrated that conversely, CD39 can be leveraged to serve as a proxy of tumor-reactive CD8 T cells. Using single-cell CITE/RNA/TCRseq, we show that CD39+ CD8 T cells in human lung cancers demonstrate transcriptional and proteomic features of exhaustion, tumor reactivity, and clonal expansion. Moreover, TCR cloning revealed that CD39 enriched for tumor-reactive CD8 T cell clones. Flow cytometry of 440 lung cancer specimens revealed that CD39 level on CD8 T cells is only weakly correlated with tumoral features that currently guide lung cancer therapy, such as histology, driver mutation, PD-L1 and tumor mutation burden. PD-1 axis blockade, but not cytotoxic chemotherapy, increased intratumoral CD39+ CD8 T cells. CD39 correlated with PD-1 expression on CD8 T cells and high pre-treatment/early-on-treatment levels were associated with improved clinical outcomes, but not immune-related adverse events, from immune checkpoint blockade therapy. This comprehensive profiling of the clinical, pathological and molecular features highlights the utility of CD39 as a proxy for tumor-reactive CD8 T cells in human lung cancer..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
bioRxiv.org - (2022) vom: 07. Juni Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.1101/2022.01.24.477554 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI035098295 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI035098295 | ||
| 003 | DE-627 | ||
| 005 | 20230429093725.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220129s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2022.01.24.477554 |2 doi | |
| 035 | |a (DE-627)XBI035098295 | ||
| 035 | |a (biorXiv)10.1101/2022.01.24.477554 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Chow, Andrew |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CD39 Identifies Tumor-Reactive CD8 T cells in Patients With Lung Cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT The repertoire of tumor-infiltrating lymphocytes (TILs) can be vast, and many of these TILs are not endowed with tumor reactivity. While a number of reports have shown that tumor-reactive TILs express CD39, few reports have demonstrated that conversely, CD39 can be leveraged to serve as a proxy of tumor-reactive CD8 T cells. Using single-cell CITE/RNA/TCRseq, we show that CD39+ CD8 T cells in human lung cancers demonstrate transcriptional and proteomic features of exhaustion, tumor reactivity, and clonal expansion. Moreover, TCR cloning revealed that CD39 enriched for tumor-reactive CD8 T cell clones. Flow cytometry of 440 lung cancer specimens revealed that CD39 level on CD8 T cells is only weakly correlated with tumoral features that currently guide lung cancer therapy, such as histology, driver mutation, PD-L1 and tumor mutation burden. PD-1 axis blockade, but not cytotoxic chemotherapy, increased intratumoral CD39+ CD8 T cells. CD39 correlated with PD-1 expression on CD8 T cells and high pre-treatment/early-on-treatment levels were associated with improved clinical outcomes, but not immune-related adverse events, from immune checkpoint blockade therapy. This comprehensive profiling of the clinical, pathological and molecular features highlights the utility of CD39 as a proxy for tumor-reactive CD8 T cells in human lung cancer. | ||
| 700 | 1 | |a Uddin, Fathema Z. |e verfasserin |4 aut | |
| 700 | 1 | |a Mangarin, Levi |e verfasserin |4 aut | |
| 700 | 1 | |a Rizvi, Hira |e verfasserin |4 aut | |
| 700 | 1 | |a Dobrin, Anton |e verfasserin |4 aut | |
| 700 | 1 | |a Tischfield, Sam |e verfasserin |4 aut | |
| 700 | 1 | |a Quintanal-Villalonga, Alvaro |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Joseph M. |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Nisargbhai |e verfasserin |4 aut | |
| 700 | 1 | |a Allaj, Viola |e verfasserin |4 aut | |
| 700 | 1 | |a Manoj, Parvathy |e verfasserin |4 aut | |
| 700 | 1 | |a Mattar, Marissa |e verfasserin |4 aut | |
| 700 | 1 | |a Meneses, Maximiliano |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Landau, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Ward, Mariana |e verfasserin |4 aut | |
| 700 | 1 | |a Kulick, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Kwong, Charlene |e verfasserin |4 aut | |
| 700 | 1 | |a Wierzbicki, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Yavner, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Chavan, Shweta S. |e verfasserin |4 aut | |
| 700 | 1 | |a Farillas, Abigail |e verfasserin |4 aut | |
| 700 | 1 | |a Holland, Aliya |e verfasserin |4 aut | |
| 700 | 1 | |a Sridhar, Harsha |e verfasserin |4 aut | |
| 700 | 1 | |a Ciampricotti, Metamia |e verfasserin |4 aut | |
| 700 | 1 | |a Hirschhorn, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Richards, Allison L |e verfasserin |4 aut | |
| 700 | 1 | |a Donoghue, Mark T.A. |e verfasserin |4 aut | |
| 700 | 1 | |a Heller, Glenn |e verfasserin |4 aut | |
| 700 | 1 | |a Klebanoff, Christopher A. |e verfasserin |4 aut | |
| 700 | 1 | |a Hellmann, Matthew D. |e verfasserin |4 aut | |
| 700 | 1 | |a de Stanchina, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Sen, Triparna |e verfasserin |4 aut | |
| 700 | 1 | |a Wolchok, Jedd D. |e verfasserin |4 aut | |
| 700 | 1 | |a Merghoub, Taha |e verfasserin |4 aut | |
| 700 | 1 | |a Rudin, Charles M. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2022) vom: 07. Juni |
| 773 | 1 | 8 | |g year:2022 |g day:07 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2022.01.24.477554 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 07 |c 06 | ||
| 953 | |2 045F |a 570 | ||